MedTrace Logo

Phase 4 IOP Signals Associated With ILUVIEN®

NCT02424019 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 153

Last updated 2022-01-11

No results posted yet for this study

Summary

This study will assess the safety in patients treated with ILUVIEN, with primary focus on IOP.

Conditions

  • Diabetic Macular Edema (DME)

Interventions

DRUG

ILUVIEN 0.19 MG

Sponsors & Collaborators

  • Alimera Sciences

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-05-06
Primary Completion
2020-07-29
Completion
2020-07-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02424019 on ClinicalTrials.gov